 
                                                                                We increased our Target Price for Biotalys to € 7.5 (was €6.1) while maintaining our Buy rating after Biotalys announced that the US EPA (Environmental Protection Agency) has issued its proposed registration decision to approve its first biofungicide, Evoca. The EPA will now initiate the final phase in its regulatory review, allowing stakeholders such as growers and industry associations 15 days to provide feedback before finalizing its regulatory decision. The EPA has also posted a final rule e...
 
                                                                                Arcadis: Feedback from conference call 3Q25. Belgian telcos: Telenet positive net adds in broadband, near ECM decision. CTP: 34k sqm lease signed in Poland. Eurocommercial Properties: Organic momentum is getting stronger. Fugro: Reasonable 3Q, challenging 4Q and beyond. Heijmans: Order book quality improves further. KPN: VodafoneZiggo guidance maintained, ECM decision near. Proximus: CPaaS peer Twilio reports strong 3Q25 results. Retail Estates: Jysk new tenant of 5 Leen Bakker B...
 
                                                                                Eurocommercial reports results in line with our expectations at EUR 1.85 direct investment result per share vs. 1.83 KBCSe (+1.1% YoY). The rental income growth accelerated at 3.6% like-for-like (1.7% above inflation) driven by rent reversion, stable (+10bps) vacancy and higher retail sales (+4.1% vs 2.6% in 1H25). The like-for-like growth is mainly driven by the Italian portfolio at +5.1%. The average rent collection dropped from 99.0% to 98.0% coming from the French portfolio (92% in 3Q25). Th...
 
                                                                                AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
 
                                                                                Recticel saw 3Q revenue decline by 1% which was below our and consensus forecasts. Recticel reiterated FY25 adjusted EBITDA guidance calling for c. 10% growth. The strategic growth projects in the US (Insulated Panels Plant) and Belgium (Recycling plant) are progressing according to plan. While we still believe in the strategic attractiveness of the insulation market and Recticel's offering, we deem short term valuation multiples are about fair so we maintain our Hold rating and € 11 target pric...
 
                                                                                UCB announced new 3-year data for Bimzelx in adults with active psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) at ACR 2025. The results show sustained responses in both patient groups, and appear competitive vs. other biologics e.g. Cosentyx in cross-trial comparison. Overall supportive data that should maintain Bimzelx' commercial momentum. ACCUMULATE maintained.
 
                                                                                A director at UCB SA bought 70 shares at 250.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
 
                                                                                We update our model with added cautiousness on the top line but leave our bottom line and NTA projections almost unchanged. Our FY26-28F earnings CAGR is at c.2%. Despite some problematic tenants (Leen Bakker, Casa and Carpetright, accounting for c.2.5% of rents), Retail Estates has a history of being capable of quick/efficient reletting and good tenant mix improvement on the back of this. We confirm our positive stance on the company, which currently trades at a 21.3% NTA discount to its FY26F ...
 
    
 
            Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.